

Cover Story
As biomedical research at NIH faces an existential threat from the Trump administration, an entrepreneur is winning over allies for what he describes as a “simple idea” that could introduce a massive new infusion of money for innovation in medicine.
Cancer Policy


In Brief
Clinical Roundup


Drugs & Targets
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- Senators slam Bhattacharya for deflecting responsibility for NIH cuts, upheaval
Susan Collins: Trump’s 40% cut is “so disturbing” - In the Headlines: Missing record of NCAB meetings restored to NIH website
- Insights from ASCO 2025: Real-world evidence drives clinical decision-making
- The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
Directors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it” - GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation